Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk is keen to replicate Ozempic's success. It just made two acquisitions that could lead to another big victory.

Novo Nordisk Is Already Working on Ozempic 2.0. Here's How to Profit

Eli Lilly

SoFi Technologies

Due to what could be an unsustainable rally for equities, you may be looking for Nasdaq stocks to sell now. We've had an incredible run this year, but there are some additional indiciations that our luck has come to an end.

3 Nasdaq Stocks to Sell in September Before They Crash & Burn

Novo Nordisk is now the biggest company in Europe with a valuation of more than $425 billion. The biotech company has taken over luxury goods maker LVMH in market cap size.

CHART OF THE DAY: Ozempic maker Novo Nordisk overtakes LVMH to become the biggest company in Europe

Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.

Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues

American depositary receipts of Novo Nordisk (NVO) climbed 1.5% in early trading on Tuesday after launching its popular weight-loss drug, Wegovy, in the U.K.

Novo Nordisk Becomes Europe's Most Valuable Company as Wegovy Launches in UK

Launch of weight-loss drug in UK helps Danish firm to market value of $428bn

Wegovy maker Novo Nordisk becomes Europe's most valuable firm

Novo Nordisk has dethroned Bernard Arnault's luxury goods giant LVMH as Europe's most valuable company.

The maker of Wegovy and Ozempic is now Europe's most valuable company

Novo Nordisk has been trading places with LVMH for the title of Europe's most valuable company. The Danish pharmaceutical giant makes the buzzy weight-loss drugs Wegovy and Ozempic.

Business is booming for the maker of weight-loss drugs Wegovy and Ozempic — so much so that it is threatening luxury giant LVMH's crown as Europe's most valuable firm

The pharma company's Wegovy medication helps it overtake luxury goods maker LVMH, with a market value of around $420 billion.

Novo Nordisk Is Now Europe's Biggest Company, Driven by Weight-Loss Drug. How Eli Lilly Could Benefit.

UK-based Simple Online Pharmacy has received stock of Novo Nordisk's weight-loss drug Wegovy, a company spokesperson said on Tuesday, one day after Novo launched the drug in Britain.

Wegovy supply from Novo Nordisk has arrived in UK, Simple Online Pharmacy says

Novo Nordisk A/S (NYSE: NVO) is in focus on Monday after it launched its weight loss drug in another European market – the United Kingdom. Novo Nordisk is facing supply constraints But the pharmaceutical behemoth did confirm that the weekly injection will initially be available via NHS only to a limited number of eligible patients.

Novo Nordisk rolls out its weight loss drug Wegovy in the U.K.

People in Britain who can afford to pay out of their own pocket may get easier access to Novo Nordisk's weight-loss drug Wegovy than those seeking treatment in the country's state-run health service, some doctors and medical experts warned on Monday.

Pent-up private Wegovy demand prompts UK availability concerns

Several prominent UK-based insurers including Aviva, Axa, and WPA will not cover the costs of the newly launched weight-loss drug, Wegovy, under their private medical insurance policies.  Since insurers typically cover acute conditions, which are characterised as diseases, illnesses, or injuries that are likely to respond quickly to treatment, the so-called “miracle” obesity drug developed by Novo Nordisk (NYSE:NVO) does not qualify.

‘Miracle' weight-loss drug Wegovy will not be issued through major insurers

Novo Nordisk launched its Wegovy weight loss injection in the U.K. Monday, furthering the drug's rollout in Europe despite ongoing supply constraints.

Novo Nordisk's Wegovy weight loss drug launches in the UK

Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe and Japan, even as it struggles to keep up with demand.

Launches of Novo Nordisk's weight-loss drug Wegovy

Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe even as it struggles to keep up with demand. The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle drug.

Factbox: Launches of Novo Nordisk's weight-loss drug Wegovy

Novo Nordisk has launched its wildly popular weight-loss drug Wegovy in nine countries since 2021 at prices ranging from $200 to almost $2,000 a month as Eli Lilly starts selling its rival drug in Europe and the United States.

Launches and prices of Novo Nordisk's weight-loss drug Wegovy

Novo Nordisk has launched its wildly popular weight-loss drug Wegovy in 10 countries since 2021 at prices ranging from $200 to almost $2,000 a month as Eli Lilly starts selling its rival drug in Europe and the United States.

Weight-loss drug Wegovy: How much does it cost and where is it sold?

In August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.

Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New Peak

Novo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.

Novo Nordisk launches weight-loss drug Wegovy in UK

The maker of diabetes and weight-loss drugs Ozempic and Wegovy beat out the French luxury retailer behind brands like Louis Vuitton and Dior.

Ozempic Drug Maker Briefly Becomes Europe's Most Valuable Company

LVMH, which has been Europe's most valuable company for two-and-a-half years, was briefly overtaken on Friday by Ozempic maker Novo Nordisk.

Ozempic maker briefly overtook LVMH as Europe's most valuable company

Novo Nordisk (NYSE:NVO) became Europe's largest company for a short time today as investors continued to pile into the Danish drugmaker following the recent trial of fat-busting drug Wegovy. Shares in Novo have jumped 17% since the trial showed that not only can Wegovy trim the waistline but cuts the risk of heart attack or stroke by a fifth.

Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks

Astellas Pharma Inc

Amgen

Bristol-Myers

Horizon Pharma

Johnson & Johnson

Merck

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Danish drugmaker Novo Nordisk briefly unseated LVMH as Europe's most valuable listed company in intraday trading on Friday, ending the French luxury group's 2-1/2 year-long reign at the top.

News for Novo Nordisk Stock (NVO)